The JAKoMo study highlights ruxolitinib's long-term efficacy and safety in myelofibrosis, showing improved quality of life ...

These interviews are the top episodes, by listens, from among the 21 podcast episodes The American Journal of Managed Care® ...

ATLAS trial investigator Guy Young, MD, Children's Hospital Los Angeles and University of Southern California Keck School of ...

The symptoms of dry eye are multifactorial, says Mina Massaro-Giordano, MD, making identifying and treating dry eye important ...

Thirty-three states, the District of Columbia, and Puerto Rico will participate in CMS’ voluntary Cell and Gene Therapy (CGT) ...

Panelists discuss the drivers and consequences of delayed diagnosis in hidradenitis suppurativa, emphasizing the need for ...

National Minority Mental Health Month emphasizes the persistent mental health disparities among US racial and ethnic ...

Panelists discuss how reaching underserved populations requires proactive outreach, digital health tools with appropriate ...

Panelists discuss how BTK inhibitors represent a promising new oral therapy class that could address both inflammatory and ...

Panelists discuss how payers can evaluate BTK inhibitors by considering specific MS phenotypes and FDA indications rather ...

Panelists discuss how clinical decision support tools, care pathways, and artificial intelligence can address primary care ...

The FDA determined the data from STARGLO did not provide sufficient evidence to support approving glofitamab-gxbm (Columvi) in combination with gemcitabine and oxaliplatin to treat relapsed/refractory ...